老虎證券

BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon

Reuters
04/29
BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon

April 29 (Reuters) - Orchestra Biomed Holdings Inc OBIO.O:

  • ORCHESTRA BIOMED RECEIVES FDA APPROVAL OF IDE TO INITIATE U.S. CORONARY PIVOTAL TRIAL RANDOMIZING FIRST-IN-CLASS SIROLIMUS-ANGIOINFUSION BALLOON, VIRTUE SAB, HEAD-TO-HEAD WITH PACLITAXEL-COATED BALLOON

  • ORCHESTRA BIOMED HOLDINGS INC: TARGETING INITIATION OF VIRTUE TRIAL DURING SECOND HALF OF 2025

Source text: ID:nGNX9CRyqk

Further company coverage: OBIO.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10